Antibody Drug Conjugates (ADCs) entered clinical trials in the mid 1990s to selectively deliver cytotoxic chemotherapy to cancer cells with the goal to increase the antitumor activity and decrease normal tissue toxicity. Over nearly 30 years of development the ADC platform has become established with now 11 approved agents and many more in the pipeline. This review is designed to highlight some of the problems and solutions encountered in clinical development as well as provide practical instruction to both clinical investigators on the efficient protocol design for ADCs and the lessons learned.

中文翻译：

---

抗体偶联药物：临床开发中的注意事项

抗体药物偶联物 (ADC) 在 1990 年代中期进入临床试验，选择性地向癌细胞提供细胞毒性化学疗法，目的是增加抗肿瘤活性并降低正常组织毒性。经过近 30 年的发展，ADC 平台已经建立，现在有 11 家获得批准的代理商，还有更多正在筹备中。本综述旨在强调临床开发中遇到的一些问题和解决方案，并为临床研究人员提供有关 ADC 高效方案设计和经验教训的实用指导。